Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy

NCT02768714 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Strategic changes regarding the product development

Conditions

Breast Cancer

Interventions

DRUG: Eurofarma's pegfilgrastim
DRUG: Neulastim

Sponsor

Eurofarma Laboratorios S.A.